Cue Biopharma Inc V.CUE

Primary Symbol: CUE

Healthcare Biotechnology

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

NDAQ:CUE - Post by User

Cue Biopharma Inc > Take over - White Canyon Uranium Ltd WU

<< Previous

Bullboard Posts

Next >>

Comment by adit123on Feb 24, 2011 9:26am

204 Views

Post# 18186078

RE: Take over - White Canyon Uranium Ltd WU

See my post from 14 Feb. where I report my talk with IR--I suspect things will drift about until those drill results come out and then a new resource estimate. What interests me is the fact the property is literally surrounded by the UrAmerican property (private uranium company); seems they would want the resource as they are a producer. But I have not seen anything discuss that possibility.

<< Previous

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment